Diagnostic and Prognostic Molecular Markers in Renal Cell Carcinoma

Hari S G R Tunuguntla, Merce Jorda

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: We reviewed the contemporary literature on molecular biomarkers in renal cell carcinoma and their prognostic significance. Materials and Methods: Articles published during 1981 to 2007 in English on renal cell carcinoma were surveyed using the MEDLINE®/PubMed® database. The subject headings included were genetics, biomarkers, prognosis and risk models of renal cell carcinoma. We present a synthesis of currently known renal cell carcinoma biomarkers at various stages of development and their clinical significance, and prognostic nomograms incorporating biomarkers. Results: The beneficiary role of biomarkers in renal cell carcinoma is challenged by the relatively low prevalence of the disease. Even if a biomarker for renal cell carcinoma had 100% sensitivity and 99.4% specificity, the positive predictive value of the marker in men older than 65 years would be only 10%. Several biomarkers are being investigated in renal cell carcinoma, of which many relate to pathogenic molecular changes that are currently therapeutic targets. Carbonic anhydrase IX is a von Hippel-Lindau mediated enzyme that is expressed in most renal cell carcinoma cases. High (greater than 85%) expression of this marker indicates favorable prognosis and may predict the response to interleukin-2 therapy. B7-H1 expression in renal cell carcinoma cells/lymphocytes may indicate worse survival, possibly through impaired host antitumor immunity. Prognostic nomograms incorporating clinical variables and molecular markers to refine the prediction of treatment outcomes are in active development and await prospective clinical validation. Conclusions: Several renal cell carcinoma molecular markers appear promising to refine the prognosis and prediction of localized, advanced or metastatic renal cell carcinoma. Currently carbonic anhydrase IX is the best studied and promising marker. Prospective, multicenter clinical validation aimed at the practical clinical usefulness of renal cell carcinoma biomarkers is warranted.

Original languageEnglish
Pages (from-to)2096-2102
Number of pages7
JournalJournal of Urology
Volume179
Issue number6
DOIs
StatePublished - Jun 1 2008

Fingerprint

Molecular Pathology
Renal Cell Carcinoma
Biomarkers
Nomograms
Literature
PubMed
MEDLINE
Interleukin-2
Immunity
Databases
Lymphocytes

Keywords

  • biological
  • carcinoma
  • diagnosis
  • kidney
  • prognosis
  • renal cell
  • tumor markers

ASJC Scopus subject areas

  • Urology

Cite this

Diagnostic and Prognostic Molecular Markers in Renal Cell Carcinoma. / Tunuguntla, Hari S G R; Jorda, Merce.

In: Journal of Urology, Vol. 179, No. 6, 01.06.2008, p. 2096-2102.

Research output: Contribution to journalArticle

Tunuguntla, Hari S G R ; Jorda, Merce. / Diagnostic and Prognostic Molecular Markers in Renal Cell Carcinoma. In: Journal of Urology. 2008 ; Vol. 179, No. 6. pp. 2096-2102.
@article{466ae1d1e00245b5b4b284d8b3ed9ba5,
title = "Diagnostic and Prognostic Molecular Markers in Renal Cell Carcinoma",
abstract = "Purpose: We reviewed the contemporary literature on molecular biomarkers in renal cell carcinoma and their prognostic significance. Materials and Methods: Articles published during 1981 to 2007 in English on renal cell carcinoma were surveyed using the MEDLINE{\circledR}/PubMed{\circledR} database. The subject headings included were genetics, biomarkers, prognosis and risk models of renal cell carcinoma. We present a synthesis of currently known renal cell carcinoma biomarkers at various stages of development and their clinical significance, and prognostic nomograms incorporating biomarkers. Results: The beneficiary role of biomarkers in renal cell carcinoma is challenged by the relatively low prevalence of the disease. Even if a biomarker for renal cell carcinoma had 100{\%} sensitivity and 99.4{\%} specificity, the positive predictive value of the marker in men older than 65 years would be only 10{\%}. Several biomarkers are being investigated in renal cell carcinoma, of which many relate to pathogenic molecular changes that are currently therapeutic targets. Carbonic anhydrase IX is a von Hippel-Lindau mediated enzyme that is expressed in most renal cell carcinoma cases. High (greater than 85{\%}) expression of this marker indicates favorable prognosis and may predict the response to interleukin-2 therapy. B7-H1 expression in renal cell carcinoma cells/lymphocytes may indicate worse survival, possibly through impaired host antitumor immunity. Prognostic nomograms incorporating clinical variables and molecular markers to refine the prediction of treatment outcomes are in active development and await prospective clinical validation. Conclusions: Several renal cell carcinoma molecular markers appear promising to refine the prognosis and prediction of localized, advanced or metastatic renal cell carcinoma. Currently carbonic anhydrase IX is the best studied and promising marker. Prospective, multicenter clinical validation aimed at the practical clinical usefulness of renal cell carcinoma biomarkers is warranted.",
keywords = "biological, carcinoma, diagnosis, kidney, prognosis, renal cell, tumor markers",
author = "Tunuguntla, {Hari S G R} and Merce Jorda",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.juro.2008.01.083",
language = "English",
volume = "179",
pages = "2096--2102",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Diagnostic and Prognostic Molecular Markers in Renal Cell Carcinoma

AU - Tunuguntla, Hari S G R

AU - Jorda, Merce

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Purpose: We reviewed the contemporary literature on molecular biomarkers in renal cell carcinoma and their prognostic significance. Materials and Methods: Articles published during 1981 to 2007 in English on renal cell carcinoma were surveyed using the MEDLINE®/PubMed® database. The subject headings included were genetics, biomarkers, prognosis and risk models of renal cell carcinoma. We present a synthesis of currently known renal cell carcinoma biomarkers at various stages of development and their clinical significance, and prognostic nomograms incorporating biomarkers. Results: The beneficiary role of biomarkers in renal cell carcinoma is challenged by the relatively low prevalence of the disease. Even if a biomarker for renal cell carcinoma had 100% sensitivity and 99.4% specificity, the positive predictive value of the marker in men older than 65 years would be only 10%. Several biomarkers are being investigated in renal cell carcinoma, of which many relate to pathogenic molecular changes that are currently therapeutic targets. Carbonic anhydrase IX is a von Hippel-Lindau mediated enzyme that is expressed in most renal cell carcinoma cases. High (greater than 85%) expression of this marker indicates favorable prognosis and may predict the response to interleukin-2 therapy. B7-H1 expression in renal cell carcinoma cells/lymphocytes may indicate worse survival, possibly through impaired host antitumor immunity. Prognostic nomograms incorporating clinical variables and molecular markers to refine the prediction of treatment outcomes are in active development and await prospective clinical validation. Conclusions: Several renal cell carcinoma molecular markers appear promising to refine the prognosis and prediction of localized, advanced or metastatic renal cell carcinoma. Currently carbonic anhydrase IX is the best studied and promising marker. Prospective, multicenter clinical validation aimed at the practical clinical usefulness of renal cell carcinoma biomarkers is warranted.

AB - Purpose: We reviewed the contemporary literature on molecular biomarkers in renal cell carcinoma and their prognostic significance. Materials and Methods: Articles published during 1981 to 2007 in English on renal cell carcinoma were surveyed using the MEDLINE®/PubMed® database. The subject headings included were genetics, biomarkers, prognosis and risk models of renal cell carcinoma. We present a synthesis of currently known renal cell carcinoma biomarkers at various stages of development and their clinical significance, and prognostic nomograms incorporating biomarkers. Results: The beneficiary role of biomarkers in renal cell carcinoma is challenged by the relatively low prevalence of the disease. Even if a biomarker for renal cell carcinoma had 100% sensitivity and 99.4% specificity, the positive predictive value of the marker in men older than 65 years would be only 10%. Several biomarkers are being investigated in renal cell carcinoma, of which many relate to pathogenic molecular changes that are currently therapeutic targets. Carbonic anhydrase IX is a von Hippel-Lindau mediated enzyme that is expressed in most renal cell carcinoma cases. High (greater than 85%) expression of this marker indicates favorable prognosis and may predict the response to interleukin-2 therapy. B7-H1 expression in renal cell carcinoma cells/lymphocytes may indicate worse survival, possibly through impaired host antitumor immunity. Prognostic nomograms incorporating clinical variables and molecular markers to refine the prediction of treatment outcomes are in active development and await prospective clinical validation. Conclusions: Several renal cell carcinoma molecular markers appear promising to refine the prognosis and prediction of localized, advanced or metastatic renal cell carcinoma. Currently carbonic anhydrase IX is the best studied and promising marker. Prospective, multicenter clinical validation aimed at the practical clinical usefulness of renal cell carcinoma biomarkers is warranted.

KW - biological

KW - carcinoma

KW - diagnosis

KW - kidney

KW - prognosis

KW - renal cell

KW - tumor markers

UR - http://www.scopus.com/inward/record.url?scp=43049109844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049109844&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.01.083

DO - 10.1016/j.juro.2008.01.083

M3 - Article

C2 - 18423738

AN - SCOPUS:43049109844

VL - 179

SP - 2096

EP - 2102

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -